THTomoki Hashimoto

Tomoki Hashimoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tomoki Hashimoto has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Kosuke Wada

    From the Departments of Anesthesia and Perioperative Care (K.S., H.F., K.W., M.K., Y.W., A.K., F.S., T.H.) and Neurological Surgery (M.T.L.), University of California, San Francisco; and Department of Neurosurgery (K.S., M.K., Y.T., K.T.K., S.N.), School of Medicine, The University of Tokushima, Tokushima City, Japan

    8 shared publications
  • Yasuhisa Kanematsu

    The University of Tokushima

    8 shared publications
  • Yoshiteru Tada

    From the Departments of Anesthesia and Perioperative Care (K.S., H.F., K.W., M.K., Y.W., A.K., F.S., T.H.) and Neurological Surgery (M.T.L.), University of California, San Francisco; and Department of Neurosurgery (K.S., M.K., Y.T., K.T.K., S.N.), School of Medicine, The University of Tokushima, Tokushima City, Japan

    8 shared publications
  • Elena I. Liang

    ‡ Department of Anesthesia and Perioperative Care

    7 shared publications
  • Hiroshi Makino

    ‡ Department of Anesthesia and Perioperative Care

    7 shared publications
  • Chie Kurihara

    6 shared publications

Latest Publications

  • Mouse Models of Aortic Aneurysm

    by Miyuki Kanematsu, Yasuhisa Kanematsu, Tomoki Hashimoto

  • Protective Role of Peroxisome Proliferator–Activated Receptor-γ in the Development of Intracranial Aneurysm Rupture

    by Kenji Shimada, Hajime Furukawa, Kosuke Wada, Masaaki Korai, Yuan Wei, Yoshiteru Tada, Atsushi Kuwabara, Fumiaki Shikata, Keiko T. Kitazato, Shinji Nagahiro, et al.

    Background and Purpose—: Inflammation is emerging as a key component of the pathophysiology of intracranial aneurysms. Peroxisome proliferator–activated receptor-γ (PPARγ) is a nuclear hormone receptor of which activation modulates various aspects of inflammation. Methods—: Using a mouse model of intracranial aneurysm, we examined the potential roles of PPARγ in the development of rupture of intracranial aneurysm. Results—: A PPARγ agonist, pioglitazone, significantly reduced the incidence of ruptured aneurysms and the rupture rate without affecting the total incidence aneurysm (unruptured aneurysms and ruptured aneurysms). PPARγ antagonist (GW9662) abolished the protective effect of pioglitazone. The protective effect of pioglitazone was absent in mice lacking macrophage PPARγ. Pioglitazone treatment reduced the mRNA levels of inflammatory cytokines (monocyte chemoattractant factor-1, interleukin-1, and interleukin-6) that are primarily produced by macrophages in the cerebral arteries. Pioglitazone treatment reduced the infiltration of M1 macrophage into the cerebral arteries and the macrophage M1/M2 ratio. Depletion of macrophages significantly reduced the rupture rate. Conclusions—: Our data showed that the activation of macrophage PPARγ protects against the development of aneurysmal rupture. PPARγ in inflammatory cells may be a potential therapeutic target for the prevention of aneurysmal rupture.


  • Open Access

    Angiotensin-(1-7) Protects against the Development of Aneurysmal Subarachnoid Hemorrhage in Mice

    by Kenji Shimada, Hajime Furukawa, Kosuke Wada, Yuan Wei, Yoshiteru Tada, Atsushi Kuwabara, Fumiaki Shikata, Yasuhisa Kanematsu, Michael T Lawton, Keiko T Kitazato, et al.

    Angiotensin-(1-7) (Ang-(1-7)) can regulate vascular inflammation and remodeling, which are processes that have important roles in the pathophysiology of intracranial aneurysms. In this study, we assessed the effects of Ang-(1-7) in the development of intracranial aneurysm rupture using a mouse model of intracranial aneurysms in which aneurysmal rupture (i.e., aneurysmal subarachnoid hemorrhage) occurs spontaneously and causes neurologic symptoms. Treatment with Ang-(1-7) (0.5 mg/kg/day), Mas receptor antagonist (A779 0.5 mg/kg/day or 2.5 mg/kg/day), or angiotensin II type 2 receptor (AT2R) antagonist (PD 123319, 10 mg/kg/day) was started 6 days after aneurysm induction and continued for 2 weeks. Angiotensin-(1-7) significantly reduced the rupture rate of intracranial aneurysms without affecting the overall incidence of aneurysms. The protective effect of Ang-(1-7) was blocked by the AT2R antagonist, but not by the Mas receptor antagonist. In AT2R knockout mice, the protective effect of Ang-(1-7) was absent. While AT2R mRNA was abundantly expressed in the cerebral arteries and aneurysms, Mas receptor mRNA expression was very scarce in these tissues. Angiotensin-(1-7) reduced the expression of tumor necrosis factor-α and interleukin-1β in cerebral arteries. These findings indicate that Ang-(1-7) can protect against the development of aneurysmal rupture in an AT2R-dependent manner.


  • Roles of Estrogen in the Formation of Intracranial Aneurysms in Ovariectomized Female Mice

    by Yoshiteru Tada, Hiroshi Makino, Hajime Furukawa, Kenji Shimada, Kosuke Wada, Elena I. Liang, Shoko Murakami, Mari Kudo, David K. Kung, David M. Hasan, et al.

    Background:. Epidemiological studies have indicated that postmenopausal women have a higher incidence of intracranial aneurysms than men in the same age


  • Estrogen Protects Against Intracranial Aneurysm Rupture in Ovariectomized Mice

    by Yoshiteru Tada, Kosuke Wada, Kenji Shimada, Hiroshi Makino, Elena I. Liang, Shoko Murakami, Mari Kudo, Fumiaki Shikata, Ricardo A. Pena Silva, Keiko T. Kitazato, et al.

    Clinical observations suggest that postmenopausal women have a higher incidence of aneurysmal rupture than premenopausal women. We hypothesize that a relative deficiency in estrogen may increase the risks of aneurysmal growth and subarachnoid hemorrhage in postmenopausal women. We assessed the effects of estrogen and selective estrogen receptor subtype agonists on the development of aneurysmal rupture in ovariectomized female mice. We used an intracranial aneurysm mouse model that recapitulates the key features of human intracranial aneurysms, including spontaneous rupture. Ten- to 12-week-old ovariectomized female mice received treatment with estrogen, nonselective estrogen receptor antagonist, estrogen receptor-α agonist, or estrogen receptor-β agonist starting 6 days after aneurysm induction so that the treatments affected the development of aneurysmal rupture without affecting aneurysmal formation. Estrogen significantly reduced the incidence of ruptured aneurysms and rupture rates in ovariectomized mice. Nonselective estrogen receptor antagonist abolished the protective effect of estrogen. Although estrogen receptor-α agonist did not affect the incidence of ruptured aneurysms or rupture rates, estrogen receptor-β agonist prevented aneurysmal rupture without affecting the formation of aneurysms. The protective role of estrogen receptor-β agonist was abolished by the inhibition of nitric oxide synthase. We showed that estrogen prevented aneurysmal rupture in ovariectomized female mice. The protective effect of estrogen seemed to occur through the activation of estrogen receptor-β, a predominant subtype of estrogen receptor in human intracranial aneurysms and cerebral arteries.


  • Translational Research Using a Mouse Model of Intracranial Aneurysm

    by Kosuke Wada, Hiroshi Makino, Kenji Shimada, Fumiaki Shikata, Atsushi Kuwabara, Tomoki Hashimoto

    We have developed a mouse model of intracranial aneurysm that recapitulates key features of human intracranial aneurysms. In this model, spontaneous aneurysmal rupture occurs with a predictable time course. Aneurysmal rupture in this model can be easily detected by assessing neurological symptoms. Similar to human intracranial aneurysms, intracranial aneurysms in this model show an infiltration with inflammatory cells. This mouse model can be used to study the mechanisms and the potential preventive treatments for aneurysmal rupture.


  • Open Access

    Macrophage imbalance (M1 vs. M2) and upregulation of mast cells in wall of ruptured human cerebral aneurysms: preliminary results

    by David Hasan, Nohra Chalouhi, Pascal Jabbour, Tomoki Hashimoto

    M1 and M2 cells are two major subsets of human macrophages that exert opposite effects on the inflammatory response. This study aims to investigate the role of macrophage M1/M2 imbalance and mast cells in the progression of human cerebral aneurysms to rupture. Ten patients with cerebral aneurysms (five ruptured and five unruptured) underwent microsurgical clipping. During the procedure, a segment of the aneurysm dome was resected and immunostained with monoclonal antibodies for M1 cells (anti-HLA DR), M2 cells (anti-CD 163), and mast cells (anti-tryptase clone AA). A segment of the superficial temporal artery (STA) was also removed and immunostained with monoclonal antibodies for M1, M2, and mast cells. All ten aneurysm tissues stained positive for M1, M2, and mast cells. M1 and M2 cells were present in equal proportions in unruptured aneurysms. This contrasted with a marked predominance of M1 over M2 cells in ruptured aneurysms (p = 0.045). Mast cells were also prominently upregulated in ruptured aneurysms (p = 0.001). Few M1 and M2 cells were present in STA samples. M1/M2 macrophages and mast cells are found in human cerebral aneurysms; however, M1 and mast cell expression seems to markedly increase in ruptured aneurysms. These findings suggest that macrophage M1/M2 imbalance and upregulation of mast cells may have a role in the progression of cerebral aneurysms to rupture.


  • Pharmacological Stabilization of Intracranial Aneurysms in Mice

    by Hiroshi Makino, Yoshiteru Tada, Kosuke Wada, Elena I. Liang, Mayland Chang, Shahriar Mobashery, Yasuhisa Kanematsu, Chie Kurihara, Emma Palova, Miyuki Kanematsu, et al.

    Background and Purpose—: An increasing number of unruptured intracranial aneurysms are being detected, partly due to the increased use of brain imaging techniques. Pharmacological stabilization of aneurysms for the prevention of aneurysmal rupture could potentially be an attractive alternative approach to clipping or coiling in patients with unruptured intracranial aneurysms. We have developed a mouse model of intracranial aneurysm that recapitulates key features of intracranial aneurysms. In this model, subarachnoid hemorrhage from aneurysmal rupture causes neurological symptoms that can be easily detected by a simple neurological examination. Using this model, we tested whether anti-inflammatory agents such as tetracycline derivatives, or a selective inhibitor of matrix metalloproteinases-2 and -9 (SB-3CT), can prevent the rupture of intracranial aneurysms. Methods—: Aneurysms were induced by a combination of induced hypertension and a single injection of elastase into the cerebrospinal fluid in mice. Treatment with minocycline, doxycycline, or SB-3CT was started 6 days after aneurysm induction. Aneurysmal rupture was detected by neurological symptoms and confirmed by the presence of intracranial aneurysms with subarachnoid hemorrhage. Results—: Minocycline and doxycycline significantly reduced rupture rates (vehicle versus doxycycline=80% versus 35%, P P P =0.53). Conclusions—: Our data established the feasibility of using a mouse model of intracranial aneurysm to test pharmacological stabilization of aneurysms. Tetracycline derivatives could be potentially effective in preventing aneurysmal rupture.


  • Animal Models of Intracranial Aneurysms

    by Elena I. Liang, Hiroshi Makino, Yoshiteru Tada, Kosuke Wada, Tomoki Hashimoto


  • A Mouse Model of Intracranial Aneurysm: Technical Considerations

    by Yoshiteru Tada, Yasuhisa Kanematsu, Miyuki Kanematsu, Yoshitsugu Nuki, Elena I. Liang, Kosuke Wada, Hiroshi Makino, Tomoki Hashimoto

    Intracranial aneurysms can be induced by a single stereotaxic injection of elastase into the cerebrospinal fluid at the right basal cistern in hypertensive mice. This mouse model produces large aneurysm formations with an incidence of 60–80% within 3–4 weeks. Intracranial aneurysms in this model recapitulate key pathological features of human intracranial aneurysms. Several technical factors are critical for the successful induction of intracranial aneurysms in this model. Precise stereotaxic placement of the needle tip into the cerebrospinal fluid space is especially important. Aneurysm formations in this model can serve as a simple and easily interpretable outcome for future studies that utilize various inhibitors, knockout mice, or transgenic mice to test roles of specific molecules and pathways in the pathophysiology of intracranial aneurysms.